S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
Log in
NASDAQ:VRCA

Verrica Pharmaceuticals Stock Forecast, Price & News

$12.64
+0.94 (+8.03 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.68
Now: $12.64
$12.68
50-Day Range
$9.79
MA: $11.16
$12.63
52-Week Range
$6.02
Now: $12.64
$17.60
Volume132,548 shs
Average Volume78,539 shs
Market Capitalization$326.95 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica Pharmaceuticals Inc. was founded in 2013 and is headquartered in West Chester, Pennsylvania.
Verrica Pharmaceuticals logo

MarketRank

Overall MarketRank

1.10 out of 5 stars

Medical Sector

685th out of 1,922 stocks

Pharmaceutical Preparations Industry

347th out of 769 stocks

Analyst Opinion: 2.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRCA
CUSIPN/A
CIKN/A
Phone484-453-3300
Employees17

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.52 per share

Profitability

Net Income$-28,210,000.00

Miscellaneous

Market Cap$326.95 million
Next Earnings Date3/12/2021 (Estimated)
OptionableNot Optionable
$12.64
+0.94 (+8.03 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

How has Verrica Pharmaceuticals' stock been impacted by COVID-19?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VRCA stock has increased by 20.2% and is now trading at $12.64.
View which stocks have been most impacted by COVID-19
.

Is Verrica Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Verrica Pharmaceuticals stock.
View analyst ratings for Verrica Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Verrica Pharmaceuticals?

Wall Street analysts have given Verrica Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Verrica Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Verrica Pharmaceuticals
.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) issued its earnings results on Monday, November, 9th. The company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.01.
View Verrica Pharmaceuticals' earnings history
.

What price target have analysts set for VRCA?

4 Wall Street analysts have issued 12-month target prices for Verrica Pharmaceuticals' stock. Their forecasts range from $10.00 to $21.00. On average, they anticipate Verrica Pharmaceuticals' share price to reach $15.75 in the next twelve months. This suggests a possible upside of 24.6% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Verrica Pharmaceuticals' key competitors?

What other stocks do shareholders of Verrica Pharmaceuticals own?

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:
  • Mr. Ted White, Pres, CEO & Director (Age 55, Pay $666.19k)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 53, Pay $342.85k)
  • Mr. Joe Bonaccorso, Chief Commercial Officer (Age 56, Pay $528.11k)
  • Dr. Gary Goldenberg M.D., Chief Medical Officer (Age 43, Pay $55k)
  • Mr. Christopher G. Hayes, Chief Legal Officer, Sec. & Gen. Counsel (Age 56)
  • Mr. Eugene Scavola, Exec. VP of Technical Operations
  • Dr. Bradley J. Catalone MBA, Ph.D., Head of Drug Devel.

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $12.64.

How big of a company is Verrica Pharmaceuticals?

Verrica Pharmaceuticals has a market capitalization of $326.95 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 17 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.